Author:
Morgado-Carrasco D.,Ibaceta J.,Iranzo P.,Bosch-Amate X.,Mascaró-Galy J.M.
Reference9 articles.
1. Anticoagulation with rivaroxaban for livedoid vasculopathy (RILIVA): a multicentre, single-arm, open-label, phase 2a, proof-of-concept trial;Weishaupt;Lancet Haematol,2016
2. Rivaroxaban for treatment of livedoid vasculopathy: a systematic review;Gao;Dermatol Ther,2021
3. Livedoid vasculopathy in Koreans: clinical features and response to rivaroxaban treatment;Lee;J Eur Acad Dermatol Venereol,2020
4. Livedoid vasculopathy in 75 Brazilian patients in a single-center institution: clinical, histopathological and therapy evaluation;Criado;Dermatol Ther,2021
5. Treatment of livedoid vasculopathy with rivaroxaban: a potential use of new oral anticoagulants for dermatologists;Jiménez-Gallo;Actas Dermosifiliogr (Engl Ed),2018